A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
Active, not recruiting · Phase 1 · NCT02988960
Conditions: Advanced Solid Tumors Cancer
At a glance
- Research payments reported, 2025
- $239
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 163
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-927 (drug), ABBV-927 (drug), ABBV-181 (drug)
- Dates
- Started 2017-02-22; completion 2026-09
- Results posted
- Not yet
This is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of ABBV-927, and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181 in participants with advanced solid tumors.
From ClinicalTrials.gov, last updated 2026-01-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $239 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dana Farberpartners Cancer Care in $239
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.